Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[13/08/2018]

UCB : UCB Media Room: FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray

FDA Accepts New Drug Application NDA to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clustersMidazolam Nasal Spray has been granted orphan drug designation by the United States Food and Drug Administration US FDA for the rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity e.g. seizure... See more
 
UCB [BE0003739530/UCB]   
[10/08/2018]

UCB : UCB Media Room: Transparency Notification

Transparency notification BlackRock, Inc.Brussels Belgium, 10 August 2018 – 20:00 CEST – regulated information1. Summary of the notificationPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from BlackRock, Inc. having its registered office at 55 East 52nd Street, New York, NY, 10055,... See more
 
UCB [BE0003739530/UCB]   
[08/08/2018]

UCB : UCB Media Room: Transparency Notification

Transparency notifications BlackRock, Inc.4 notifications referring to situation on 1, 2, 3 and 6 August 2018Threshold crossed: 5%Latest holding: 5.04%Brussels Belgium, 8 August 2018 – 20:00 CEST – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 4 transparency... See more
 
UCB [BE0003739530/UCB]   
[03/08/2018]

UCB : UCB Media Room: Transparency Notification

Transparency notifications BlackRock, Inc.2 notifications referring to situation on 30 July and 31 July 2018Threshold crossed: 5%Latest holding: 5.02%Brussels Belgium, 3 August 2018 – 20:00 CEST – regulated informationSummary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency... See more
 
UCB [BE0003739530/UCB]   
[26/07/2018]

UCB : UCB Media Room: Half Year Results 2018

UCB Half Year Report 2018:UCB continues its growth pathBrussels Belgium, 26 July 2018 – 7:00 CEST – regulated information –Revenue reached € 2.27 billion: 2%, 6% CER;net sales increased to € 2.15 billion: 5%, 10% CER.Underlying profitability rEBITDA increased to € 794 million: 7%, 12% CERR&D update: romosozumab resubmission in the U.S.Financial outlook for 2018 confirmed: Revenue... See more
 
UCB [BE0003739530/UCB]